# Q702 for the Treatment of Patients With Hematologic Malignancies

> **NCT06712810** · PHASE1 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 46 (estimated)

## Conditions studied

- Hematopoietic and Lymphatic System Neoplasm
- Histiocytic Sarcoma
- Malignant Histiocytosis
- Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Chronic Myelomonocytic Leukemia
- Recurrent Follicular Lymphoma
- Recurrent Langerhans Cell Histiocytosis
- Recurrent Lymphoplasmacytic Lymphoma
- Recurrent Myelodysplastic Syndrome
- Recurrent Myelofibrosis
- Recurrent Small Lymphocytic Lymphoma
- Recurrent Waldenstrom Macroglobulinemia
- Refractory Chronic Lymphocytic Leukemia
- Refractory Chronic Myelomonocytic Leukemia
- Refractory Erdheim-Chester Disease
- Refractory Follicular Lymphoma
- Refractory Langerhans Cell Histiocytosis
- Refractory Lymphoplasmacytic Lymphoma
- Refractory Myelodysplastic Syndrome
- Refractory Myelofibrosis
- Refractory Small Lymphocytic Lymphoma
- Refractory Waldenstrom Macroglobulinemia
- Rosai-Dorfman-Destombes Disease
- Primary Central Nervous System Lymphoma
- Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
- Recurrent Erdheim-Chester Disease
- Recurrent Fibroblastic Reticular Cell Sarcoma
- Recurrent Histiocytic Sarcoma
- Recurrent Interdigitating Dendritic Cell Sarcoma
- Recurrent Rosai-Dorfman-Destombes Disease
- Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm
- Refractory Fibroblastic Reticular Cell Sarcoma
- Refractory Histiocytic Sarcoma
- Refractory Interdigitating Dendritic Cell Sarcoma
- Refractory Rosai-Dorfman-Destombes Disease

## Interventions

- **DRUG:** Axl/Mer/CSF1R Inhibitor Q702
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Positron Emission Tomography
- **OTHER:** Survey Administration

## Key facts

- **NCT ID:** NCT06712810
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-27
- **Primary completion:** 2030-09-15
- **Final completion:** 2030-09-15
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2025-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06712810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06712810, "Q702 for the Treatment of Patients With Hematologic Malignancies". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06712810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*